CQP 201-403 in Parkinson's disease: An open-label pilot study

Ronald Pfeiffer, L. H. Herrera, C. S. Glaeske, R. E. Hofman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalMovement Disorders
Volume4
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Parkinson Disease
Hypokinesia
Dopamine Agonists
Tremor
Psychotic Disorders
Hospitalization
CQP 201-403
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pfeiffer, R., Herrera, L. H., Glaeske, C. S., & Hofman, R. E. (1989). CQP 201-403 in Parkinson's disease: An open-label pilot study. Movement Disorders, 4(3), 278-281.

CQP 201-403 in Parkinson's disease : An open-label pilot study. / Pfeiffer, Ronald; Herrera, L. H.; Glaeske, C. S.; Hofman, R. E.

In: Movement Disorders, Vol. 4, No. 3, 1989, p. 278-281.

Research output: Contribution to journalArticle

Pfeiffer, R, Herrera, LH, Glaeske, CS & Hofman, RE 1989, 'CQP 201-403 in Parkinson's disease: An open-label pilot study', Movement Disorders, vol. 4, no. 3, pp. 278-281.
Pfeiffer, Ronald ; Herrera, L. H. ; Glaeske, C. S. ; Hofman, R. E. / CQP 201-403 in Parkinson's disease : An open-label pilot study. In: Movement Disorders. 1989 ; Vol. 4, No. 3. pp. 278-281.
@article{930f9aec5112434bbad94e51adf6a180,
title = "CQP 201-403 in Parkinson's disease: An open-label pilot study",
abstract = "The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.",
author = "Ronald Pfeiffer and Herrera, {L. H.} and Glaeske, {C. S.} and Hofman, {R. E.}",
year = "1989",
language = "English (US)",
volume = "4",
pages = "278--281",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - CQP 201-403 in Parkinson's disease

T2 - An open-label pilot study

AU - Pfeiffer, Ronald

AU - Herrera, L. H.

AU - Glaeske, C. S.

AU - Hofman, R. E.

PY - 1989

Y1 - 1989

N2 - The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.

AB - The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0024403765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024403765&partnerID=8YFLogxK

M3 - Article

C2 - 2571083

AN - SCOPUS:0024403765

VL - 4

SP - 278

EP - 281

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 3

ER -